共 50 条
- [31] A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2017, 23 (16) : 4642 - 4650Britten, Carolyn D.Garrett-Mayer, ElizabethChin, Steven H.Shirai, KeisukeOgretmen, BesimBentz, Tricia A.Brisendine, AlanAnderton, KateCusack, Susan L.Maines, Lynn W.Zhuang, YanSmith, Charles D.Thomas, Melanie B.
- [32] A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumorsMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Tsimberidou, ApostoliaVandross, Andrae L.Sommerhalder, DavidJoseph, CharmaineChandhasin, ChandtipPerabo, FrankClarke, Michael F.
- [33] First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced MesotheliomaJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S384 - S384Yap, T.Desai, J.Dagogo-Jack, I.Millward, M.Kindler, H. L.Tolcher, A. W.Frentzas, S.Body, A. L.Thurston, A.Post, L.Dorr, F. A.Kwiatkowski, D. J.
- [34] Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Sachdev, Jasgit C.Bauer, Todd MichaelChawla, Sant P.Pant, ShubhamPatnaik, AmitaWainberg, Zev A.Inamdar, Sandeep P.Marina, NeyssaSun, StefanieSchmidt, MaikeXiang, HongLoRusso, Patricia
- [35] Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Paluri, Ravi KumarLi, PengJones, Benjamin ScottMadan, AnkitJerome, MaryMiley, DebiKeef, JenniferRobert, Francisco
- [36] ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Palmer, Daniel H.Symeonides, Stefan N.Dempsey, Fiona C.Crichton, Scott J.Tennant, ColinWood, Christopher B.Knight, RuthBalabanova, SilviyaUpton, ClareLow, Samantha S. P.Proudfoot-Jones, JemmaJaved, Sohail RoomanSkolariki, AglaiaBlagden, Sarah Patricia
- [37] Final results of a phase 1 trial of sorafenib, pemetrexed, and cisplatin in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Alharbi, Abeer F.Kirstein, Mark N.Fujioka, Naomi
- [38] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +Razak, Albiruni R. AbdulMau-Soerensen, MortenGabrail, Nashat Y.Gerecitano, John F.Shields, Anthony F.Unger, Thaddeus J.Saint-Martin, Jean R.Carlson, RobertLandesman, YosefMcCauley, DilaraRashal, TamiLassen, UlrikKim, RichardStayner, Lee-AnneMirza, Mansoor R.Kauffman, MichaelShacham, SharonMahipal, Amit
- [39] Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Lynch, Ryan C.Munster, Pamela N.Advani, Ranjana H.Hamadani, MehdiSpigel, David R.Falchook, Gerald StevenPatel, Manish R.Siegel, David Samuel DiCapuaBeri, NinaNowakowski, Grzegorz S.Palmisiano, NeilBurness, Monika LeighMoore, Kathleen N.Shapiro, GeoffreyJuric, DejanBradley, William D.O'Shea, Thomas J.Renschler, Markus FredericEnglert, Judson M.Yap, Timothy A.
- [40] A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Sharp, AdamWilliams, AnjaBlagden, Sarah PatriciaPlummer, Elizabeth RuthHochhauser, DanielKrebs, MatthewPacey, SimonEvans, T. R. JeffryWhelan, SarahNandakumar, SrinandRogers, SeemaJameson, Katherine L.Basile, Frank G.De Bono, Johann S.Arkenau, Hendrik-Tobias